Semaglutide doses typically range from 0.25mg to 2.4mg per week, while retatrutide can escalate up to 12mg per week
While numbers do not tell the entire story, they do represent significant innovation in patient care and advance public health for the American public
Timing for combination protocols Some researchers use GLP-1 agonists alongside other peptides or medications
Unlike traditional GLP-1 medications, Retatrutide activates three hormone pathways simultaneously: This is why it is often referred to as a triple agonist therapy
This triple agonist approach has shown in research models to enhance insulin sensitivity, suppress appetite, and increase basal energy expenditure
However, like all medicines, oral Semaglutide can cause side-effects